Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.
The annual challenge of the global health community is progressing innovative products (vaccines, antiviral drugs, immunomodulators) for the control of infections of significant disease burden in a timely manner at an optimum cost. hVIVO and its associated laboratory services provides a single, centralised testing ability to reduce time and costs and provide specialised scientific design services throughout all phases of your development program.